{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:23:43Z","timestamp":1715646223040},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,9,1]]},"DOI":"10.2169\/internalmedicine.0865-22","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T06:44:11Z","timestamp":1669790651000},"page":"2507-2511","source":"Crossref","is-referenced-by-count":0,"title":["Ledipasvir\/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir\/Pibrentasvir"],"prefix":"10.2169","volume":"62","author":[{"given":"Takushi","family":"Manabe","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan"},{"name":"Department of Gastroenterology and Hepatology, Takamatsu Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Tadokoro","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Ohura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joji","family":"Tani","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asahiro","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikara","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Takamatsu Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Masaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12: 671-675, 1990.","DOI":"10.1002\/hep.1840120409"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Nagata H, Nakagawa M, Asahina Y, et al. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol 67: 933-939, 2017.","DOI":"10.1016\/j.jhep.2017.05.028"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kanda T, Yasui S, Nakamura M, et al. Real-world experiences with the combination treatment of ledipasvir plus sofosbuvir for 12 weeks in HCV genotype 1-infected Japanese patients: achievement of a sustained virological response in previous users of peginterferon plus ribavirin with HCV NS3\/4A inhibitors. Int J Mol Sci 18: 906, 2017.","DOI":"10.3390\/ijms18050906"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Iio E, Shimada N, Takaguchi K, et al. Clinical evaluation of sofosbuvir\/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir\/asunaprevir therapy. Hepatol Res 47: 1308-1316, 2017.","DOI":"10.1111\/hepr.12898"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ng TI, Krishnan P, Pilot-Matias T, et al. In vitro antiviral activity and resistance profile of the next generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother 61: e02558, 2017.","DOI":"10.1128\/AAC.02558-16"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ng T, Tripathi R, Reisch T, et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3\/4A protease inhibitor glecaprevir. Antimicrob Agents Chemother 62: e01620, 2017.","DOI":"10.1128\/AAC.01620-17"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Chayama K, Suzuki F, Karino Y, et al. Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol 53: 557-565, 2018.","DOI":"10.1007\/s00535-017-1391-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kumada H, Watanabe T, Suzuki F, et al. Efficacy and safety of glecaprevir\/pibrentasvir in HCVinfected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol 53: 566-575, 2018.","DOI":"10.1007\/s00535-017-1396-0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sezaki H, Suzuki F, Hosaka T, et al. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1\/2\/3 infections. J Gastroenterol 54: 916-927, 2019.","DOI":"10.1007\/s00535-019-01575-9"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Izumi N, Takehara T, Chayama K, et al. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int 12: 356-367, 2018.","DOI":"10.1007\/s12072-018-9878-6"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Krishnan P, Schnell G, Tripathi R, et al. Integrated resistance analysis of CERTAIN-1 and CERTAIN-2 studies in hepatitis C virus-infected patients receiving glecaprevir and pibrentasvir in Japan. Antimicrob Agents Chemother 62: e02217, 2017.","DOI":"10.1128\/AAC.02217-17"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Uemura H, Uchida Y, Kouyama J, et al. NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir. J Gastroenterol 54: 459-470, 2019.","DOI":"10.1007\/s00535-018-01543-9"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Doi A, Hikita H, Sakamori R, et al. Nonstructural protein 5A\/P32 deletion after failure of ledipasvir\/sofosbuvir in hepatitis C virus genotype 1b infection. Hepatology 68: 380-383, 2018.","DOI":"10.1002\/hep.29836"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Itakura J, Kurosaki M, Hasebe C, et al. Complex pattern of resistance-associated substitutions of hepatitis C virus after daclatasvir\/asunaprevir treatment failure. PLoS One 11: e0165339, 2016.","DOI":"10.1371\/journal.pone.0165339"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Akuta N, Sezaki H, Suzuki F, et al. Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens. J Med Virol 91: 102-106, 2019.","DOI":"10.1002\/jmv.25278"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ogawa E, Furusyo N, Nakamuta M, et al. Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: results from a multicenter, real-world cohort study. Hepatol Res 49: 617-626, 2019.","DOI":"10.1111\/hepr.13328"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Osawa M, Imamura M, Teraoka Y, et al. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. J Gastroenterol 54: 291-296, 2019.","DOI":"10.1007\/s00535-018-1520-9"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tsuji K, Kurosaki M, Itakura J, et al. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Gastroenterol 53: 1142-1150, 2018.","DOI":"10.1007\/s00535-018-1455-1"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kwon H, Xing W, Chan K, et al. Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent. PLoS One 10: e0122844, 2015.","DOI":"10.1371\/journal.pone.0122844"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Hayashi K, Ishigami M, Ishizu Y, et al. Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy. J Viral Hepat 25: 1446-1451, 2018.","DOI":"10.1111\/jvh.12967"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Minosse C, Gruber CE, Rueca M, et al. Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs. Viruses 13: 1151, 2021.","DOI":"10.3390\/v13061151"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/17\/62_0865-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:28:33Z","timestamp":1715574513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/17\/62_0865-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":21,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0865-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]},"article-number":"0865-22"}}